Literature DB >> 31611501

Physiological significance of ghrelin in the cardiovascular system.

Takeshi Tokudome1, Kenji Kangawa2.   

Abstract

Ghrelin, a growth hormone-releasing peptide first discovered in rat stomach in 1999, is a ligand for the growth hormone secretagogue receptor. It participates in the regulation of diverse processes, including energy balance and body weight maintenance, and appears to be beneficial for the treatment of cardiovascular diseases. In animal models of chronic heart failure, ghrelin improves cardiac function and remodeling; these findings have been recapitulated in human patients. In other animal models, ghrelin effectively diminishes pulmonary hypertension. Moreover, ghrelin administration early after myocardial infarction decreased the frequency of fatal arrhythmia and improved survival rate. In ghrelin-deficient mice, endogenous ghrelin protects against fatal arrhythmia and promotes remodeling after myocardial infarction. Although the mechanisms underlying the effects of ghrelin on the cardiovascular system have not been fully elucidated, its beneficial effects appear to be mediated through regulation of the autonomic nervous system. Ghrelin is a promising therapeutic agent for cardiac diseases.

Entities:  

Keywords:  GHS-R; cardiovascular system; ghrelin

Mesh:

Substances:

Year:  2019        PMID: 31611501      PMCID: PMC6819151          DOI: 10.2183/pjab.95.032

Source DB:  PubMed          Journal:  Proc Jpn Acad Ser B Phys Biol Sci        ISSN: 0386-2208            Impact factor:   3.493


  38 in total

1.  Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves.

Authors:  Yuanjie Mao; Takeshi Tokudome; Kentaro Otani; Ichiro Kishimoto; Michio Nakanishi; Hiroshi Hosoda; Mikiya Miyazato; Kenji Kangawa
Journal:  Endocrinology       Date:  2012-04-25       Impact factor: 4.736

Review 2.  Ghrelin and the heart.

Authors:  Takeshi Tokudome; Kentaro Otani; Mikiya Miyazato; Kenji Kangawa
Journal:  Peptides       Date:  2018-05-20       Impact factor: 3.750

3.  One dose of ghrelin prevents the acute and sustained increase in cardiac sympathetic tone after myocardial infarction.

Authors:  Daryl O Schwenke; Takeshi Tokudome; Ichiro Kishimoto; Takeshi Horio; Patricia A Cragg; Mikiyasu Shirai; Kenji Kangawa
Journal:  Endocrinology       Date:  2012-03-20       Impact factor: 4.736

4.  Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure.

Authors:  N Nagaya; K Miyatake; M Uematsu; H Oya; W Shimizu; H Hosoda; M Kojima; N Nakanishi; H Mori; K Kangawa
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

5.  Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure.

Authors:  N Nagaya; M Uematsu; M Kojima; Y Ikeda; F Yoshihara; W Shimizu; H Hosoda; Y Hirota; H Ishida; H Mori; K Kangawa
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

6.  Treatment of cachexia with ghrelin in patients with COPD.

Authors:  Noritoshi Nagaya; Takefumi Itoh; Shinsuke Murakami; Hideo Oya; Masaaki Uematsu; Kunio Miyatake; Kenji Kangawa
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

7.  Growth hormone secretagogue binding sites in peripheral human tissues.

Authors:  M Papotti; C Ghè; P Cassoni; F Catapano; R Deghenghi; E Ghigo; G Muccioli
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

8.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

9.  Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction.

Authors:  Takeshi Soeki; Ichiro Kishimoto; Daryl O Schwenke; Takeshi Tokudome; Takeshi Horio; Morikatsu Yoshida; Hiroshi Hosoda; Kenji Kangawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-11-16       Impact factor: 4.733

10.  Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats.

Authors:  Yingzi Lin; Kiyoshi Matsumura; Masayo Fukuhara; Shuntaro Kagiyama; Koji Fujii; Mitsuo Iida
Journal:  Hypertension       Date:  2004-03-01       Impact factor: 10.190

View more
  6 in total

1.  The ghrelin-GHSR-1a pathway inhibits high glucose-induced retinal angiogenesis in vitro by alleviating endoplasmic reticulum stress.

Authors:  Rong Li; Guomin Yao; Lingxiao Zhou; Min Zhang; Jin Yan
Journal:  Eye Vis (Lond)       Date:  2022-06-07

Review 2.  Research progress of ghrelin on cardiovascular disease.

Authors:  Ming-Jie Yuan; Wei Li; Peng Zhong
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

3.  Ghrelin Ameliorates Diabetic Retinal Injury: Potential Therapeutic Avenues for Diabetic Retinopathy.

Authors:  Jie Bai; Fan Yang; Ruiqi Wang; Qinghui Yan
Journal:  Oxid Med Cell Longev       Date:  2021-10-26       Impact factor: 6.543

4.  Analysis of the miRNA-mRNA Regulatory Network Reveals the Biomarker Genes in the Progression of Myocardial Ischemic Reperfusion.

Authors:  Nini Li; Qing Chen
Journal:  J Healthc Eng       Date:  2022-04-13       Impact factor: 3.822

5.  Comparison of the effects of different calorie amounts of enteral nutrition in hypercatabolism associated with ghrelin-POMC in endotoxemic rats.

Authors:  Jianfeng Duan; Minhua Cheng; Yali Xu; Shaoqiu Tang; Xiaoyao Li; Yan Chen; Huimin Lu; Tao Gao; Wenkui Yu
Journal:  Nutr Metab (Lond)       Date:  2022-04-15       Impact factor: 4.654

Review 6.  Ghrelin octanoylation by ghrelin O-acyltransferase: protein acylation impacting metabolic and neuroendocrine signalling.

Authors:  Tasha R Davis; Mariah R Pierce; Sadie X Novak; James L Hougland
Journal:  Open Biol       Date:  2021-07-28       Impact factor: 6.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.